__timestamp | Eli Lilly and Company, LLY, Q1 | Eli Lilly and Company, LLY, Q2 | Eli Lilly and Company, LLY, Q4 | GSK plc, GSK, Q2 | GSK plc, GSK, Q3 |
---|---|---|---|---|---|
Sunday, January 1, 2023 | 0.1932327586 | 0.2121244932 | 0.2341073834 | 0.2262468654 | 0.1796980484 |
Monday, January 1, 2024 | 0.2558052007 | 0.2625013271 | 0.148782344 |
Data in motion
In the ever-evolving pharmaceutical industry, understanding the financial health of key players is crucial. This analysis delves into the net income margins of GlaxoSmithKline (GSK), AstraZeneca, Takeda, and Eli Lilly over the past two years, providing a snapshot of their profitability.
Eli Lilly has shown remarkable consistency, with its net income margin peaking at approximately 26% in Q2 2024. Despite a slight dip to around 19% in Q1 2023, the company has maintained a strong financial position, reflecting its robust business model and strategic initiatives.
GSK's net income margin has experienced some fluctuations, with a high of nearly 23% in Q2 2023 and a low of about 15% in Q2 2024. These variations highlight the challenges and opportunities faced by the company in a competitive market.
It's important to note that some data points are missing, particularly for Q4 2024 for Eli Lilly and Q3 2024 for GSK. These gaps suggest the need for cautious interpretation and further investigation into the underlying factors.
This comparative analysis underscores the dynamic nature of the pharmaceutical sector. By closely monitoring these financial metrics, stakeholders can gain valuable insights into the strategic directions and market positions of these industry leaders.
5 Year Trend in Average Market Capitalization for AbbVie
Annual Comparison of SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline
Average Market Capitalization of Abbvie Annually
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Number of Employees for Top 10 Pharma Companies
5 Year Trend in Average Market Capitalization for AbbVie
5 Year Trend in Market Capitalization for AbbVie
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Number of Employees for Top 10 Healthcare Companies
Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters